Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Abstract

AbstractBackgroundWilms tumour (WT) is one of the cancer types targeted by the Global Initiative for Childhood Cancer (GICC). The objective of this study was to describe the outcomes of Wilms Africa Phase II in sub‐Saharan Africa.MethodsWilms Africa Phase II used a comprehensive WT treatment protocol in a multi‐centre, prospective study conducted in eight hospitals in Ethiopia (2), Ghana (2), Malawi, Cameroon, Zimbabwe and Uganda. Eligibility criteria were: age younger than 16 years, unilateral WT, diagnosed between 1 January 2021 and 31 December 2022.ResultsWe included 230 WT patients, median age 3 years, 53% male. Median maximum tumour diameter at diagnosis was 13.6 cm and 33% of patients had metastatic disease. Nephrectomy was performed in 71% of patients, of whom 21% had a tumour rupture. Two‐year event‐free survival (EFS) was 41.3% ± 3.9% after a median follow‐up of 17 months (range: 1–33 months), with treatment abandonment considered an event. Treatment abandonment occurred in 26% and death during treatment in 14%. Disease relapse occurred in 10%. Two‐year EFS of the 26 patients who received radiotherapy was 64.5% ± 9.7% with no reported disease relapse.ConclusionPatients continue to present late with advanced WT in sub‐Saharan Africa, and their survival is below the 60% GICC target. Prevention of treatment abandonment and treatment‐related mortality remain important. Earlier diagnosis and access to radiotherapy are expected to decrease disease‐related mortality.